Literature DB >> 20018271

Comparison of different prime-boost regimes with DNA and recombinant Orf virus based vaccines expressing glycoprotein D of pseudorabies virus in pigs.

E M A van Rooij1, F A M Rijsewijk, H W Moonen-Leusen, A T J Bianchi, H-J Rziha.   

Abstract

Both DNA and Orf virus (ORFV; Parapox virus) based vaccines have shown promise as alternatives for conventional vaccines in pigs against pseudorabies virus (PRV) infection causing Aujeszky's disease. In the present study we evaluated the efficacy of different prime-boost regimes in pigs in terms of immunogenicity and protection against challenge infection with PRV. The different prime-boost regimes consisted of the homologous prime-boost regimes (DNA followed by DNA or ORFV followed by ORFV) and the heterologous prime-boost regimes (DNA followed by ORFV and ORFV followed by DNA), all based on glycoprotein D (gD) of PRV. Moreover, we compared the efficacy of the different prime-boost regimes with the efficacy of a conventional modified live vaccine (MLV). The different prime-boost regimes resulted in different levels of immunity and protection against challenge infection. Most effective was the regime of priming with DNA vaccine followed by boosting with the ORFV based vaccine. This regime resulted in strong antibody responses, comparable to the antibody responses obtained after prime-boost vaccination with a conventional MLV vaccine. Also with regard to protection, the prime DNA-boost ORFV regime performed better than the other prime-boost regimes. This study demonstrates the potential of a heterologous prime-boost vaccination strategy against PRV based on a single antigen, and that in the natural host, the pig. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20018271     DOI: 10.1016/j.vaccine.2009.12.004

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Use of Staby(®) technology for development and production of DNA vaccines free of antibiotic resistance gene.

Authors:  Anca Reschner; Sophie Scohy; Gaëlle Vandermeulen; Marc Daukandt; Céline Jacques; Benjamin Michel; Hans Nauwynck; Florence Xhonneux; Véronique Préat; Alain Vanderplasschen; Cédric Szpirer
Journal:  Hum Vaccin Immunother       Date:  2013-06-04       Impact factor: 3.452

2.  Orf Virus-Based Therapeutic Vaccine for Treatment of Papillomavirus-Induced Tumors.

Authors:  M Schneider; M Müller; A Yigitliler; J Xi; C Simon; T Feger; H-J Rziha; F Stubenrauch; H-G Rammensee; T Iftner; R Amann
Journal:  J Virol       Date:  2020-07-16       Impact factor: 5.103

3.  Orf virus (ORFV) ANK-1 protein mitochondrial localization is mediated by ankyrin repeat motifs.

Authors:  Krzysztof Lacek; Berthilde Bauer; Krystyna Bieńkowska-Szewczyk; Hanns-Joachim Rziha
Journal:  Virus Genes       Date:  2014-04-18       Impact factor: 2.332

4.  A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein.

Authors:  Ralf Amann; Jörg Rohde; Ulrich Wulle; Douglas Conlee; Rudiger Raue; Olivier Martinon; Hanns-Joachim Rziha
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

Review 5.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

6.  Structural basis of nectin-1 recognition by pseudorabies virus glycoprotein D.

Authors:  An Li; Guangwen Lu; Jianxun Qi; Lili Wu; Kegong Tian; Tingrong Luo; Yi Shi; Jinghua Yan; George F Gao
Journal:  PLoS Pathog       Date:  2017-05-19       Impact factor: 6.823

7.  New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 influenza A virus.

Authors:  Jörg Rohde; Ralf Amann; Hanns-Joachim Rziha
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

8.  Orf Virus-Based Vaccine Vector D1701-V Induces Strong CD8+ T Cell Response against the Transgene but Not against ORFV-Derived Epitopes.

Authors:  Alena Reguzova; Michael Ghosh; Melanie Müller; Hanns-Joachim Rziha; Ralf Amann
Journal:  Vaccines (Basel)       Date:  2020-06-10

9.  Genomic Characterization of Orf Virus Strain D1701-V (Parapoxvirus) and Development of Novel Sites for Multiple Transgene Expression.

Authors:  Hanns-Joachim Rziha; Mathias Büttner; Melanie Müller; Ferdinand Salomon; Alena Reguzova; Dominic Laible; Ralf Amann
Journal:  Viruses       Date:  2019-01-30       Impact factor: 5.048

10.  A Novel Orf Virus D1701-VrV-Based Dengue Virus (DENV) Vaccine Candidate Expressing HLA-Specific T Cell Epitopes: A Proof-of-Concept Study.

Authors:  Alena Reguzova; Nico Fischer; Melanie Müller; Ferdinand Salomon; Thomas Jaenisch; Ralf Amann
Journal:  Biomedicines       Date:  2021-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.